Literature DB >> 9063245

Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection.

O Weijtens1, F A van der Sluijs, R C Schoemaker, E G Lentjes, A F Cohen, F P Romijn, J C van Meurs.   

Abstract

PURPOSE: To study the dexamethasone level reached in human vitreous after a peribulbar injection of 5 mg of dexamethasone disodium phosphate and to assess its systemic uptake.
METHODS: In a prospective study, 61 eyes of 61 patients scheduled for vitrectomy received a single peribulbar injection of 5 mg of dexamethasone disodium phosphate at varied intervals before surgery. At the start of vitrectomy, an undiluted vitreous sample was taken. In 22 patients, multiple serum samples were collected. Dexamethasone concentrations were measured by radioimmunoassay. The physiologic cortisol concentration was determined in the vitreous of 12 eyes of 12 patients who did not receive dexamethasone.
RESULTS: An average dexamethasone peak concentration of approximately 13 ng/ml was reached in vitreous 6 to 7 hours after peribulbar injection. In serum the average peak concentration was approximately 60 ng/ml 20 to 30 minutes after peribulbar injection. The average physiologic cortisol concentration in vitreous was 5.1 ng/ml.
CONCLUSIONS: After a peribulbar injection of 5 mg of dexamethasone disodium phosphate, an average intravitreal dexamethasone concentration is reached with a 75 times greater anti-inflammatory potency than physiologically present cortisol. Dexamethasone concentration in serum, however, is several times higher. Peribulbar injection is not just a local treatment but results in serum levels comparable to those achieved by a high oral dose.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9063245     DOI: 10.1016/s0002-9394(14)70131-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  28 in total

Review 1.  New developments in sustained release drug delivery for the treatment of intraocular disease.

Authors:  G Velez; S M Whitcup
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Drug delivery to the eye through systematic circulation following subconjonctival injection.

Authors:  Mesut Erdurmus; Mustafa Durmus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-22       Impact factor: 3.117

3.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

Review 4.  Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A.

Authors:  A D Dick; M Azim; J V Forrester
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

5.  MRI study of subconjunctival and intravitreal injections.

Authors:  S Kevin Li; Jinsong Hao; Hongshan Liu; Jing-huei Lee
Journal:  J Pharm Sci       Date:  2012-03-30       Impact factor: 3.534

6.  Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis.

Authors:  Pradeep Venkatesh; Zaheer Abhas; Satpal Garg; Rajpal Vohra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-08-02       Impact factor: 3.117

Review 7.  [Pharmacokinetics of systemic, regional and topical drugs for therapy of intraocular inflammation].

Authors:  M D Becker; S Lortz; B Flückiger; V Luginbuehl
Journal:  Ophthalmologe       Date:  2014-02       Impact factor: 1.059

8.  Passive and oxymetazoline-enhanced delivery with a lens device: pharmacokinetics and efficacy studies with rabbits.

Authors:  David J Miller; S Kevin Li; Anthony L Tuitupou; Rajan P Kochambilli; Kongnara Papangkorn; Donald C Mix; William I Higuchi; John W Higuchi
Journal:  J Ocul Pharmacol Ther       Date:  2008-08       Impact factor: 2.671

9.  The effect of a preoperative subconjuntival injection of dexamethasone on blood-retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial.

Authors:  Ernesto Bali; Eric J Feron; Ed Peperkamp; Marc Veckeneer; Paul G Mulder; Jan C van Meurs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-25       Impact factor: 3.117

Review 10.  Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.

Authors:  Uday B Kompella; Aniruddha C Amrite; Rashmi Pacha Ravi; Shelley A Durazo
Journal:  Prog Retin Eye Res       Date:  2013-04-17       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.